Profound Medical Net Cash Flow 2020-2025 | PROF

Profound Medical net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Profound Medical Net Cash Flow 2020-2025 | PROF

Profound Medical net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$79.5B
Zoetis (ZTS)$68B
Daiichi Sankyo, - (DSNKY)$46.9B
Takeda Pharmaceutical (TAK)$46.6B
BeOne Medicines - (ONC)$32.5B
Sandoz Group AG (SDZNY)$26.5B
Summit Therapeutics (SMMT)$20.5B
Merck (MKKGY)$17.3B
Shionogi (SGIOY)$14.6B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$11.1B
Stevanato Group S.p.A (STVN)$8.5B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.7B
Madrigal Pharmaceuticals (MDGL)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Procaps Group, S.A (PROCF)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
BioCryst Pharmaceuticals (BCRX)$1.8B